Floatz logo

SAFIMALTIB

Leukemia, Myeloid, Acute

Janssen Research & Development, LLCSmall moleculePhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

684 Active assets in the Leukemia, Myeloid, Acute cohort.

Asset / SponsorPhaseRating
Gemtuzumab
M.D. Anderson Cancer Center
Phase 4A
Cytosin-Arabinosid
Institute of Hematology & Blood Diseases Hospital, China
Phase 3BBB
AMSACRINE
University Hospital, Toulouse
Phase 4BBB
Posaconazole
AstraZeneca
Phase 4BBB
(+)-VINCRISTINE
Janssen Research & Development, LLC
Phase 3BBB

View all 50 →

Same molecule, other indications

SAFIMALTIB is also rated in:

non-Hodgkin lymphomaDormant
CCC
Indicative ·
50 / 100
View asset →
B-cell chronic lymphocytic leukemiaDormant
CCC
Indicative ·
48 / 100
View asset →
castration-resistant prostate carcinomaDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →